TMEM167B Inhibitors
Chemical inhibitors of TMEM167B can affect the protein's function through various molecular pathways. Triciribine acts by inhibiting the phosphorylation and activation of AKT, a kinase involved in signaling pathways that regulate many cellular processes. When AKT phosphorylation is hindered, downstream effects like the functional activity of TMEM167B can be reduced, since its activity may rely on AKT-mediated signaling. Similarly, LY294002 and Wortmannin target the PI3K/AKT pathway, with LY294002 being a specific inhibitor of phosphoinositide 3-kinases (PI3K), and Wortmannin serving as a potent and irreversible inhibitor of the same. By suppressing PI3K activity, these inhibitors prevent the subsequent activation of AKT, leading to a decrease in TMEM167B activity if it is AKT-dependent. Rapamycin, another inhibitor, targets the mTOR pathway, which is downstream of AKT. It specifically inhibits the mTORC1 complex, potentially attenuating TMEM167B function if it is under the control of mTOR signaling.
Other inhibitors like Palbociclib, Olaparib, SB203580, PD98059, SP600125, U0126, MG132, and Bortezomib act on different aspects of cellular signaling and regulation. Palbociclib's selective inhibition of CDK4 and CDK6 can lead to a halt in cell cycle progression, which can indirectly affect TMEM167B if it is involved in cell cycle processes. Olaparib, as a PARP inhibitor, may inhibit TMEM167B by interfering with DNA repair mechanisms. SB203580 and SP600125, specific inhibitors of p38 MAP kinase and JNK respectively, alter stress response and apoptosis pathways, which can decrease TMEM167B activity if it is associated with these pathways. PD98059 and U0126 both act as MEK inhibitors, with the latter also blocking MAPK/ERK activation, potentially reducing TMEM167B function if it is reliant on this signaling cascade. Finally, proteasome inhibitors MG132 and Bortezomib can prevent the degradation of proteins, including TMEM167B, by the ubiquitin-proteasome system. If the function of TMEM167B requires its periodic degradation, the inhibition of this process would lead to the accumulation of TMEM167B, impacting its functional activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits AKT phosphorylation and activation. Inhibition of AKT by triciribine in the signaling pathways can reduce the activity of downstream effectors that depend on AKT, including TMEM167B, thereby inhibiting TMEM167B function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 prevents the phosphorylation and activation of AKT. Since PI3K/AKT pathway activation is essential for many cellular processes, inhibiting this pathway can reduce the functional activity of TMEM167B if TMEM167B activity is AKT-dependent. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. By inhibiting PI3K, it leads to the suppression of AKT activation. As a downstream effect, TMEM167B, which may be regulated by AKT signaling, would be functionally inhibited by the reduction in AKT activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, which can inhibit the mTORC1 complex. The mTOR pathway is downstream of AKT and a critical regulator of cell growth and proliferation. Inhibition of mTOR by rapamycin can lead to reduced activity of downstream proteins, potentially including TMEM167B, thus functionally inhibiting it. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. CDKs are crucial for cell cycle progression. Inhibiting these kinases can lead to cell cycle arrest, which can indirectly inhibit the function of TMEM167B if TMEM167B is involved in cell cycle-related processes. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
Olaparib is a PARP inhibitor and inhibits the repair of DNA single-strand breaks. This can lead to synthetic lethality in cells with BRCA mutations. If TMEM167B is involved in DNA damage response pathways, its activity would be functionally inhibited as a result of compromised DNA repair mechanisms. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. The p38 MAP kinase pathway is involved in stress responses. Inhibition of p38 MAP kinase can lead to decreased activity of downstream proteins that are regulated by this pathway, including TMEM167B if it is a part of the stress response signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, which prevents the activation of ERK, a downstream component of the MAPK pathway. Inhibition of MEK and consequently ERK can decrease the activity of TMEM167B if TMEM167B's function is reliant on signaling through the ERK/MAPK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is part of the MAPK signaling pathways and is involved in the control of gene expression and apoptosis. Inhibiting JNK can inhibit the functional activity of TMEM167B if TMEM167B is associated with JNK-mediated signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which blocks the activation of MAPK/ERK. By inhibiting the MAPK/ERK pathway, U0126 can functionally inhibit TMEM167B if TMEM167B operates within this signaling cascade. | ||||||